FDA Approves Zilbrysq Autoinjector for Generalized Myasthenia Gravis Treatment

AI-generated NewsSnap summary based on source reporting.
Published: 2026-10-16
Category: health
Source: MPR / Pharmacy Times (citing UCB news release)
Original source

The U.S. FDA has approved an autoinjector formulation of Zilbrysq (zilucoplan) for treating anti-acetylcholine receptor antibody-positive generalized myasthenia gravis in adults. This new delivery method aims to simplify self-administration for patients, improving convenience for those managing the chronic autoimmune condition. Commercial availability is expected in Q1 2027.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai